EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access

Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections

Thorsten Lehr, Peter Meiser, Dominik Selzer, Torben Rixecker, Frank Holzer, Ralph Mösges, Sigrun Smola, Robert Bals, CONTAIN Study Group

JAMA Internal Medicine · 2025

DOI: 10.1001/jamainternmed.2025.4283 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JAMA Internal Medicine, 2025. Verfasst von Thorsten Lehr und 8 weiteren Autor:innen. Beteiligte Einrichtung: Saarland University, Saarbruecken, Germany. Hauptthemen laut MEDLINE: COVID-19, Phthalazines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Limited pharmaceutical options exist for preexposure prophylaxis of COVID-19 beyond vaccination. Azelastine, an antihistamine nasal spray used for decades to treat allergic rhinitis, has in vitro antiviral activity against respiratory viruses, including SARS-CoV-2.

Objective

To determine the efficacy and safety of azelastine nasal spray for prevention of SARS-CoV-2 infections in healthy adults. Design, Setting, and Participants A phase 2, double-blind, placebo-controlled, single-center trial was conducted from March 2023 to July 2024. Healthy adults from the general population were enrolled at the Saarland University Hospital in Germany.

Interventions

Participants were randomly assigned 1:1 to receive azelastine, 0.1%, nasal spray or placebo 3 times daily for 56 days. SARS-CoV-2 rapid antigen testing (RAT) was conducted twice weekly, with positive results confirmed by polymerase chain reaction (PCR). Symptomatic participants with negative RAT results underwent multiplex PCR testing for respiratory viruses. Main Outcome The primary end point was the number of PCR-confirmed SARS-CoV-2 infections during the study.

Results

A total of 450 participants were randomized, with 227 assigned to azelastine and 223 to placebo; 299 (66.4%) were female, 151 (33.6%) male, with a mean (SD) age of 33.0 (13.3) years. Most were White (417 [92.7%]), with 4 (0.9%) African, 22 (4.9%) Asian, and 7 (1.6%) of other ethnicity. In the intention-to-treat (ITT) population, the incidence of PCR-confirmed SARS-CoV-2 infection was significantly lower in the azelastine group (n = 5 [2.2%]) compared with the placebo group (n = 15 [6.7%]) (OR, 0.31; 95% CI, 0.11-0.87). As secondary end points, azelastine demonstrated an increase in mean (SD) time to SARS-CoV-2 infection among infected participants (31.2 [9.3] vs 19.5 [14.8] days), a reduction of the overall number of PCR-confirmed symptomatic infections (21 of 227 participants vs 49 of 223 participants), and a lower incidence of PCR-confirmed rhinovirus infections (1.8% vs 6.3%). Adverse events were comparable between the groups. Conclusions and Relevance In this single-center trial, azelastine nasal spray was associated with reduced risk of SARS-CoV-2 respiratory infections. These findings support the potential of azelastine as a safe prophylactic approach warranting confirmation in larger, multicentric trials.

Trial registration

EudraCT number: 2022-003756-13

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19PhthalazinesAdultFemaleHumansMaleMiddle AgedAntiviral AgentsDouble-Blind MethodNasal SpraysSARS-CoV-2

Substanzen

Antiviral AgentsazelastineNasal SpraysPhthalazines

Autor:innen und Institutionen

  • Saarland University, Saarbruecken, Germany.
  • Ursapharm Arzneimittel GmbH, Saarbruecken, Germany.
  • Department of Internal Medicine V, Saarland University Medical Center, Germany.
  • ClinCompetence Cologne GmbH, Cologne, Germany.
  • Institute of Medical Statistics and Computational Biology, University of Cologne, Germany.
  • Helmholtz Institute for Pharmaceutical Research Saarland, Germany.

Zitieren

APA

Lehr, T., Meiser, P., Selzer, D., Rixecker, T., Holzer, F., Mösges, R., Smola, S., Bals, R., & CONTAIN Study Group (2025). Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2025.4283

Vancouver

Lehr T, Meiser P, Selzer D, Rixecker T, Holzer F, Mösges R, et al. Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections. JAMA Internal Medicine. 2025. doi:10.1001/jamainternmed.2025.4283

BibTeX
@article{Lehr2025,
  author = {Lehr, Thorsten and Meiser, Peter and Selzer, Dominik and Rixecker, Torben and Holzer, Frank and Mösges, Ralph and Smola, Sigrun and Bals, Robert and CONTAIN Study Group, CONTAIN Study Group},
  title = {Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections},
  journal = {JAMA Internal Medicine},
  year = {2025},
  doi = {10.1001/jamainternmed.2025.4283}
}
Kostenlos starten →